Endpoint | Cell line | Stimulant treatment | Reference compound | Cytotoxicity test applied | Threshold for cytotoxicity | %-effect level chosen to define BEQ | International guideline documenta |
---|---|---|---|---|---|---|---|
Androgen receptor agonism (AR ago) | AR-EcoScreen GR-KO M1 | – | Dihydrotestosterone (DHT) | MTS |  ≤ 80% of vehicle control | EC20 | OECD 458 |
Androgen receptor antagonism (AR anta) | AR-EcoScreen GR-KO M1 | DHT | Hydroxyflutamide (OHF) | MTS |  ≤ 80% of vehicle control | IC30 | OECD 458 |
Estrogen receptor agonism (ER) | T47D-ER | – | 17β-estradiol (E2) | MTS |  ≤ 80% of vehicle control | EC20 | OECD 455b |
Oxidative stress (Nrf2 activity) | MCF7 AREc32 | – | tert-Butylhydroquinone (tBHQ) | MTS |  ≤ 80% of vehicle control | ECIR1.5 |  |
Aryl hydrocarbon receptor activation (AhR) | DR-EcoScreen | – | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) | MTS |  ≤ 80% of vehicle control | EC10 |  |
In vitro micronucleus test (MN) | TK-6 | – | Mitomycin C | EMA +  |  ≥ fourfold induction vs vehicle control | Not applicablec | OECD 487 |